Tin tức & Cập nhật
Lọc theo Chuyên ngành:
SGLT2 inhibitors tied to kidney benefits, reduced MACE risk
Treatment with sodium-glucose lowering co-transporter 2 inhibitors (SGLT2i) helps arrest the decline in estimated glomerular filtration rate (eGFR) and is associated with a lower risk of adverse kidney events among adults with diabetes, irrespective of baseline albuminuria status, as shown in a study presented at the recent ADA 2023.
SGLT2 inhibitors tied to kidney benefits, reduced MACE risk
17 Jul 2023
Meal replacement trumps food-based diet for improving CV risk factors in obese adults
In the secondary and exploratory analyses of the OPTIWIN trial, meal replacement (MR) outdid a food-based (FB) regimen in improving cardiometabolic risk in adults with obesity.
Meal replacement trumps food-based diet for improving CV risk factors in obese adults
17 Jul 2023
Bezlotoxumab prevents CDI recurrence in immunocompromised patients
Treatment with bezlotoxumab results in a significant decrease in recurrent Clostridioides difficile infection (CDI) in a cohort of immunocompromised patients and transplant recipients, reports a study.
Bezlotoxumab prevents CDI recurrence in immunocompromised patients
16 Jul 2023
Time to recovery from COVID-19 pneumonia similar for abatacept, cenicriviroc, infliximab
Time to recovery from COVID-19 pneumonia does not appear to differ following treatment with abatacept, cenicriviroc, or infliximab among hospitalized patients, according to a study.